New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
07:23 EDTPCRXPacira Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Pacira Pharmaceuticals to Overweight citing the FDA approval of new manufacturing capacity for Exparel. Piper believes Pacira is now able to meet the continued growth in Exparel demand and raised its price target for shares to $84 from $75.
News For PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
10:00 EDTPCRXOn The Fly: Analyst Downgrade SummaryStarz
Subscribe for More Information
07:43 EDTPCRXPacira downgraded at BofA/Merrill
Subscribe for More Information
06:17 EDTPCRXPacira downgraded to Underperform from Neutral at BofA/Merrill
Subscribe for More Information
February 25, 2015
07:26 EDTPCRXPacira price target raised to $135 from $111 at Brean Capital
Subscribe for More Information
February 24, 2015
06:43 EDTPCRXPacira sees FY15 Exparel revenue $310M-$330M
Subscribe for More Information
06:42 EDTPCRXPacira reports Q4 non-GAAP EPS 35c, consensus 28c
Reports Q4 revenue $61.8M, consensus $62.12M

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use